Breaking News Data Presented at SMFM 2022 Annual Meeting Shows Mirvie RNA Platform First to Reveal Underlying Biology of Preterm Birth
SOUTH SAN FRANCISCO–(BUSINESS WIRE)–Mirvie, a pioneer in predicting unexpected pregnancy complications, today announced that data presented at the Society for Maternal-Fetal Medicine’s 42nd Annual Pregnancy Meeting (SMFM 2022) demonstrates that Mirvie’s RNA platform is the first to predict preterm birth by revealing the underlying biology of every pregnancy. The groundbreaking research shows that the platform can predict the condition months before symptom onset and identify distinct biological pathways behind its development.
Unexpected complications affect one in five pregnancies, with significant economic costs and lifelong health consequences for mother and baby.,, Premature birth often leaves families in a state of crisis and is the primary driver of infant morbidity and mortality, frequently resulting in neonatal intensive care for baby survival. Women and physicians lack the tools to understand the underlying causes of preterm birth necessary for proactive, preventative, and personalized pregnancy care. As a result, today’s generalized treatment approaches are less effective without the benefit of targeting the underlying disease biology.
Research presented during the last SMFM 2022 session, Early prediction of spontaneous preterm birth in a high-risk population using cfRNA profiling, analyzed tens of thousands of RNA messages from 229 diverse pregnancies using the Mirvie RNA platform. In addition to predicting preterm births months before symptoms appear, the platform identified distinct underlying biological pathways driving disease development:
24 RNA messages linked to dramatic and premature changes in the mother’s cervix.
11 distinct RNA messages implicated in amino acid metabolism and growth factor pathways in extremely preterm birth.
“These groundbreaking results show that the Mirvie RNA platform can reveal fundamental biological drivers of preterm birth that were only hypothesized before. Early detection of preterm birth and identification of the distinct pathways that drive it is a This new knowledge has real potential to improve the application of existing interventions and aid in the development of new therapies for preterm birth that directly target its cause,” said Professor Rachel Tribe, Department of Women’s Health and Children, King’s College London and lead author of the research study.
The findings are based on landmark research recently published in Nature demonstration of Mirvie RNA platform can predict preeclampsia months before symptom onset. “Like preeclampsia, these preterm birth findings show that the Mirvie RNA platform is opening a new window of preventative care by revealing the underlying biology of pregnancy health and disease,” said Maneesh Jain, Ph.D., co-founder and CEO of Mirvie. “While this precision medicine approach is now common in many medical fields, pregnancy health has lagged behind for far too long. We are committed to changing this for the well-being of moms and babies and to bringing this vital information in the field.
The research was presented by Michal A. Elovitz, MD, President’s Emeritus Hilarie L. Morgan and Mitchell L. Morgan Professor Emeritus of Women’s Health at the University of Pennsylvania Perelman School of Medicine, Chief Medical Advisor at Mirvie and research co-author.
About Mirvie RNA Platform
The proprietary Mirvie RNA platform combines groundbreaking analysis of tens of thousands of RNA messages from the baby, placenta, and mother, with machine learning. The platform opens a new window into pregnancy health for women to take action and their doctors to intervene before unexpected complications become a crisis. It allows proactive, preventive and personalized pregnancy care for the well-being of mothers and babies. Mirvie conducts ongoing clinical research to validate existing peer-reviewed evidence, to improve the performance of the Mirvie RNA platform, and to improve understanding of other pregnancy complications.
Mirvie is shaping the future of pregnancy health by providing women and their physicians with an early detection window to intervene before unexpected pregnancy complications become a crisis. One in five pregnancies is affected by complications that lead to lifelong health consequences for both mother and baby. Mirvie’s proprietary RNA platform uses a simple blood test to reveal vital information about the unique biology of a pregnancy and detect complications months before they occur. The idea of Mirvie was born from the personal experience of one of the founders whose daughter was born prematurely. Mirvie’s team of world-class scientists and entrepreneurs has brought to market first-in-class, non-invasive tests for women’s health and early cancer detection, used by millions of people today . Founded in 2018, Mirvie has raised over $30 million in seed funding from leading investors including Khosla Ventures and Mayfield Fund. Mirvie is based in South San Francisco, CA. To learn more about Mirvie, please visit www.mirvie.com.
Dr. Elovitz is a scientific advisor and holds an interest in Mirvie.
: March of Dimes, Preeclampsia Foundation, IDF, CDC, WHO, UN, Sedgh et al., Reinebrant et al., McNair et al., Mirvie co-morbidity analysis.
: Sedgh G, Singh S, Hussain R. Planned and unplanned pregnancies worldwide in 2012 and recent trends. Stud family plan. (2014)